As IL-4 and IL-13 have an anti-inflammatory effect in the fat metabolism, and treatment with dupilumab blocks IL-4 and IL-13, this might interfere with activation of brown fat and thus increase the risk for obesity in patients with AD. Here, IL13 is linked to Obesity.